ArticleFrontiers in cardiovascular medicine2023
Corrigendum: Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China.
Yaohui Jiang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.